XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is bermekimab, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone512-386-2900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees56
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
XBiotech (NASDAQ:XBIT) Frequently Asked Questions
What is XBiotech's stock symbol?
XBiotech trades on the NASDAQ under the ticker symbol "XBIT."
How were XBiotech's earnings last quarter?
XBiotech Inc (NASDAQ:XBIT) posted its quarterly earnings data on Friday, August, 9th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. View XBiotech's Earnings History.
When is XBiotech's next earnings date?
What price target have analysts set for XBIT?
1 brokerages have issued twelve-month price targets for XBiotech's stock. Their forecasts range from $13.00 to $13.00. On average, they anticipate XBiotech's stock price to reach $13.00 in the next year. This suggests a possible upside of 32.8% from the stock's current price. View Analyst Price Targets for XBiotech.
What is the consensus analysts' recommendation for XBiotech?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for XBiotech.
Has XBiotech been receiving favorable news coverage?
News headlines about XBIT stock have been trending somewhat positive this week, according to InfoTrie. The research firm identifies positive and negative news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. XBiotech earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for XBiotech.
Are investors shorting XBiotech?
XBiotech saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,450,000 shares, an increase of 5.2% from the August 30th total of 3,280,000 shares. Based on an average daily trading volume, of 163,100 shares, the short-interest ratio is currently 21.2 days. Approximately 19.2% of the company's shares are sold short. View XBiotech's Current Options Chain.
Who are some of XBiotech's key competitors?
Some companies that are related to XBiotech include Nabriva Therapeutics (NBRV), Supernus Pharmaceuticals (SUPN), Ironwood Pharmaceuticals (IRWD), Madrigal Pharmaceuticals (MDGL), Eidos Therapeutics (EIDX), Opko Health (OPK), Radius Health (RDUS), Enanta Pharmaceuticals (ENTA), BELLUS Health (BLUSF), Zymeworks (ZYME), Turning Point Therapeutics (TPTX), Innoviva (INVA), Dicerna Pharmaceuticals (DRNA), ArQule (ARQL) and Endo International (ENDP).
What other stocks do shareholders of XBiotech own?
Who are XBiotech's key executives?
XBiotech's management team includes the folowing people:
- Mr. John Simard, Founder, Pres, CEO & Chairman (Age 57)
- Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 41)
- Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 52)
- Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 63)
- Dr. William Levis, Interim Medical Director and Member of Scientific Advisory Board
When did XBiotech IPO?
(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.
How do I buy shares of XBiotech?
Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is XBiotech's stock price today?
One share of XBIT stock can currently be purchased for approximately $9.79.
How big of a company is XBiotech?
XBiotech has a market capitalization of $401.50 million. The biopharmaceutical company earns $-21,140,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. XBiotech employs 56 workers across the globe.View Additional Information About XBiotech.
What is XBiotech's official website?
How can I contact XBiotech?
XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]
MarketBeat Community Rating for XBiotech (NASDAQ XBIT)
MarketBeat's community ratings are surveys of what our community members think about XBiotech and other stocks. Vote "Outperform" if you believe XBIT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XBIT will underperform the S&P 500 over the long term. You may vote once every thirty days.
